USANA Health Sciences (USNA) opened 2026 with Q1 revenue of US$250.2 million and basic EPS of US$0.41, setting a clear marker against a share price of US$20.01. The company has seen quarterly revenue range from US$213.6 million in Q4 2024 to US$250.2 million in Q1 2026, while basic EPS over that stretch has moved between a loss of US$0.36 in Q3 2025 and a gain of US$0.52 in Q2 2025. This leaves investors focused on how consistently the latest margin profile can be sustained from here.
See our full analysis for USANA Health Sciences.With the headline numbers on the table, the next step is to set these results against the most widely followed narratives around USANA’s growth, risks, and profitability to see which views hold up and which get challenged.
See what the community is saying about USANA Health Sciences
Margins Squeezed, One-Off Loss Still Lingers
- On a trailing basis, USANA generated US$925.9 million in revenue and US$8.9 million in net income, which works out to about a 1% net margin compared with 4% a year earlier, and that record also includes a one off loss of US$13.4 million in the last 12 months.
- Consensus narrative points to margin pressure from factors like regulatory and competitive risks, and the latest 1% trailing margin aligns with those concerns, yet:
- Q1 2026 net income of US$7.5 million on revenue of US$250.2 million shows the business still generated profit in the most recent period while the large one off loss dragged down the full year margin picture.
- The five year record of earnings falling about 35.8% per year and the recent 1% margin both sit uncomfortably next to hopes for stronger profitability, which is exactly the tension that cautious investors in the consensus narrative highlight.
Bears who focus on shrinking margins and that US$13.4 million one off hit will want to see how those concerns stack up against the full bear narrative before making a call on durability of future profits. 🐻 USANA Health Sciences Bear Case
High P/E Versus Peers Despite 1% Margin
- The stock trades on a trailing P/E of 41.6x against a peer average of 32.5x and an industry average of 20x, even though trailing net margin is just 1% and earnings over the past year declined from 4% margin a year earlier.
- Critics highlight that paying a higher multiple than peers could be risky if growth stalls, and the data gives them several concrete points to lean on:
- The trailing 12 month EPS of about US$0.48 and net income of US$8.9 million are held back by the one off US$13.4 million loss, so the current P/E is based on compressed earnings that may not fully reflect underlying operations.
- The current share price of US$20.01 is also well below the DCF fair value of US$73.32 in the supplied data. This creates a wide gap between what the market is paying on a P/E basis and what the DCF model indicates for long term cash flows.
Forecasted 76.9% Earnings Growth Vs 4.6% Revenue
- Analysts in the dataset expect earnings to grow about 76.9% per year over the next three years while revenue growth is forecast at 4.6% per year, compared with 11.3% for the broader US market, and they also see profit margins rising from about 1.2% to 5.4% over time.
- Consensus narrative talks about product innovation, new markets and capital allocation as drivers, and the numbers set up a clear test of that bullish angle:
- Trailing 12 month revenue of US$925.9 million compares with earlier TTM revenue of US$854.5 million a year ago, which is broadly in line with the modest 4.6% annual revenue growth embedded in forecasts rather than a rapid top line acceleration.
- At the same time, the analyst price target of US$39.00 and the DCF fair value of US$73.32 both sit well above the current US$20.01 share price. The market price therefore only fully lines up with the consensus narrative if those margin and earnings targets are met despite slower revenue growth.
Bulls who think the forecasted 76.9% earnings growth will materialize despite modest 4.6% revenue growth can compare these figures directly with the supportive arguments in the full bull case. 🐂 USANA Health Sciences Bull Case
Next Steps
To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for USANA Health Sciences on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.
If the mix of risks and rewards in this story feels finely balanced, do not wait for the next headline to decide what you think. Take a closer look at the underlying data, stress test the bull and bear arguments against your own expectations, and then ground your stance in the 2 key rewards and 3 important warning signs.
See What Else Is Out There
USANA is working with a compressed 1% trailing net margin, a relatively high P/E versus peers, and a recent history of earnings pressure.
If that mix feels a bit tight for your comfort, this is a good moment to compare it with companies that score well in our 74 resilient stocks with low risk scores so you can quickly focus on stocks where margins, earnings trends and valuations may look more resilient.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com